Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Future evaluation of telisotuzumab adizutecan in CRC in AndromMETa-560

Michael Cecchini, MD, Yale University, New Haven, CT, comments on the benefits of using telisotuzumab adizutecan with bevacizumab in an c-Met unselected colorectal cancer (CRC) patient population, highlighting improved survival compared to historical controls. Dr Cecchini mentions an ongoing the Phase III AndromMETa-560 (NCT07525206) trial, which will evaluate telisotuzumab adizutecan plus bevacizumab versus FOLFIRI plus bevacizumab, with results stratified by c-MET expression. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Well, at this point, I don’t think patients should be selected. And I think the data we reported last year at the Congress and this year at the Congress show that in an unselected patient population, when you use Temab-A in combination with Bevacizumab, that there’s benefit in PFS and OS and response rates compared to the historical controls with FOLFOX plus Bevacizumab...

Well, at this point, I don’t think patients should be selected. And I think the data we reported last year at the Congress and this year at the Congress show that in an unselected patient population, when you use Temab-A in combination with Bevacizumab, that there’s benefit in PFS and OS and response rates compared to the historical controls with FOLFOX plus Bevacizumab. So there’s an ongoing phase three study now, the AndromMETa-560, which is evaluating Temab-A, 2.4 mg per kg plus Bev, the regimen I presented today, versus FOLFOX plus Bevacizumab in an unselected patient population. These results will be stratified by c-MET expression. The trial will enroll more than 900 patients. So we will be able to look at the different levels of c-MET expression and how that correlates with efficacy. But at this time, I think the logical step forward is future enrollment in this trial in an unselected patient population.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.